Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
The purpose of this research study is to see if a drug called ritlecitinib is safe and
effective for treating chronic spontaneous urticaria (CSU). CSU is hives and itching
lasting over six weeks. Ritlecitinib is approved by the Food and Drug Administration
(FDA) to t...
Age: 18 - 65 years
Gender: All
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or exposed CIS NMIBC. Arm A will enroll 43 participants who have cancer in situ (CIS) with or without high grade papillary urothelial cancer. Arm B will enroll...
Age: 18 years - 66+
Gender: All
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of divarasib compared to
locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS
G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Age: 18 years - 66+
Gender: All
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe,
tolerable and effective in participants with advanced, or metastatic solid tumors
including urothelial cancer. The study is conducted in two parts - phase Ia
(dose-escalation, dose-o...
Age: 18 years - 66+
Gender: All
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
The purpose of this study is to measure the effect and safety of treatment with
tuvusertib combined with either niraparib or lartesertib in participants with epithelial
ovarian cancer. The participants will previously have progressed while treated with a
poly ADP rib...
Age: 18 years - 66+
Gender: Female
Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer
The overall goal of this study is to facilitate care improvements for bladder cancer patients with locally advanced or metastatic disease by designing and evaluating a patient need assessment screening tool to be used, in the future, as standard screening measure. Adult...
Age: 18 - 89 years
Gender: All
Enhancing Access to Supportive Services for Women of Color with Metastatic Breast Cancer
Black and Latina women experience disparities in supportive and palliative care access
and outcomes. The goal of the proposed pilot study is to evaluate the feasibility and
acceptability of a community navigator delivered supportive care intervention for
historically...
Age: 18 years - 66+
Gender: Female
Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
This phase II trial tests how well tailoring therapy in post-surgery works in patients
with low-risk endometrial cancer. The usual approach for patients with low-risk
endometrial cancer is treatment with surgery. In this study, tissue that is removed as
part of the s...
Age: 18 years - 66+
Gender: Female
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Some types of
cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are
looking for ways to stop the actions of abnormal proteins made from the mutated KRAS
gene. The so-c...
Age: 18 years - 66+
Gender: All
Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance.
Age: 18 years - 66+
Gender: Male
Precision Medicine Study
This will be a 2 year study to evaluate and improve cancer sequencing as applied to the
characterization of tumor molecular make-up and the identification of novel therapeutics
(n=100). Participants who will undergo tumor biopsy for management of multiple myeloma
(MM...
Age: 18 years - 66+
Gender: All
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD)
in the following tumor types: endometrial cancer (EC); head and neck squamous cell
carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC);
hepatocel...
Age: 18 years - 66+
Gender: All
A Clinical Study of V940 Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Researchers are looking for new ways to treat people with high-risk muscle-invasive
urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins
in cells that line the inside of the bladder and other parts of the urinary tract, such
as pa...
Age: 18 years - 66+
Gender: All
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
TIER-PC is an adaptive model of delivering palliative care that provides the right level of
care to the right patients at the right time. It represents an adaption of the Mount Sinai
PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. ...
Age: 18 years - 66+
Gender: All
First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial
with the goal of determining the safety of TheraSphere PCa device in patients with
clinically localized prostate cancer across US-based centers.
Age: 50 years - 66+
Gender: Male
Evaluating the Efficacy of the ENav Toolkit to Improve Colorectal Cancer Screening
The purpose of this research study is to evaluate the efficacy of a digital navigation
tool, called the eNav to improve colorectal cancer screening uptake among patients
treated at federally qualified health centers (FQHC)s. The digital navigation tool
includes a web...
Age: 45 - 75 years
Gender: All
Evaluating the Efficacy of the eNav Toolkit to Improve Colorectal Cancer Screening
The purpose of this research study is to evaluate the efficacy of a digital navigation tool,
called the eNav to improve colorectal cancer screening uptake among patients treated at
federally qualified health centers (FQHC)s. The digital navigation tool includes a we...
Age: 45 - 75 years
Gender: All
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Researchers are looking for new ways to treat people with endometrial cancer (EC) who
have previously received treatment with platinum based therapy (a type of chemotherapy)
and immunotherapy. Immunotherapy is a treatment that helps the immune system fight
cancer. Th...
Age: 18 years - 66+
Gender: Female
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
The purpose of this study is to assess if adding LY3537982 in combination with standard
of care anti-cancer drugs is more effective than standard of care in participants with
untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study
partici...
Age: 18 years - 66+
Gender: All
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study will include participants with a confirmed diagnosis of NSCLC who are deemed to...
Age: 18 years - 66+
Gender: All